Liquidia Corporation (LQDA)
| Market Cap | 2.48B +19.5% |
| Revenue (ttm) | 450.91M +2,233.6% |
| Net Income | 138.61M |
| EPS | 1.48 |
| Shares Out | 89.51M |
| PE Ratio | 18.72 |
| Forward PE | 17.26 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,306,107 |
| Open | 29.27 |
| Previous Close | 27.38 |
| Day's Range | 27.28 - 30.86 |
| 52-Week Range | 21.94 - 93.61 |
| Beta | 0.61 |
| Analysts | Buy |
| Price Target | 49.33 (+78.28%) |
| Est. Earnings | Nov 2, 2026 |
About LQDA
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company’s lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L6... [Read more]
Financial Performance
In 2025, Liquidia's revenue was $158.32 million, an increase of 1031.18% compared to the previous year's $14.00 million. Losses were -$68.92 million, -46.28% less than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for LQDA stock is "Buy." The 12-month stock price target is $49.33, which is an increase of 78.28% from the latest price.
News
Liquidia price target lowered to $38 from $40 at BofA
BofA analyst Jason Gerberry lowered the firm’s price target on Liquidia (LQDA) to $38 from $40 and keeps a Neutral rating on the shares as part of the firm’s Q3…
Liquidia director Stephen Bloch sells 235,477 shares of stock
In a regulatory filing, Liquidia (LQDA) said director Stephen Bloch sold 235,477 Liquidia shares on October 5 at an average price of $27.13, generating approximately $6.39M in proceeds. Shares of…
LQDA Investors with $100,000 in Losses Have Opportunity to Join Liquidia Corporation Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $LQDA--LQDA Investors with $100,000 in Losses Have Opportunity to Join Liquidia Corporation Fraud Investigation with SBS Law.
LQDA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Liquidia Corporation
A court finding that Yutrepia infringed two valid claims of United Therapeutics' '327 patent has put the drug's PH-ILD indication and broader availability at risk. SueWallSt notifies investors of a pe...
Liquidia price target lowered to $58 from $130 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Liquidia (LQDA) to $58 from $130 and keeps a Buy rating on the shares. The court ruling provides near-term uncertainty, but the…
Liquidia downgraded to Equal Weight from Overweight at Wells Fargo
Wells Fargo downgraded Liquidia (LQDA) to Equal Weight from Overweight with a price target of $30, down from $108. The judge’s ruling adds uncertainty to L606, the analyst tells investors…
Liquidia downgraded to Outperform from Strong Buy at Raymond James
Raymond James downgraded Liquidia to Outperform from Strong Buy with a price target of $53, down from $106. Liquidia’s (LQDA) Delaware court loss on United Therapeutics’ (UTHR) ‘327 patent removes…
United Therapeutics’ path to $1,000 ‘just got easier,’ says Cantor Fitzgerald
Cantor Fitzgerald analyst Olivia Brayer Saunders tells investors in a research note that United Therapeutics’ (UTHR) path to $1,000 “just got easier” following the patent infringement ruling over Liqu...
Liquidia price target lowered to $40 from $92 at BofA
BofA lowered the firm’s price target on Liquidia (LQDA) to $40 from $92 and keeps a Neutral rating on the shares, citing increased uncertainty surrounding Yutrepia’s commercial prospects after an…
Liquidia downgraded to Neutral from Buy at BTIG
BTIG downgraded Liquidia (LQDA) to Neutral from Buy with no price target following yesterday’s court ruling that the company infringed two claims of the ‘327 patent held by United Therapeutics…
United Therapeutics upgraded to Buy from Neutral at BTIG
BTIG upgraded United Therapeutics (UTHR) to Buy from Neutral with a $728 price target. The company’s legal win against Liquidia (LQDA) (LQDQ) “clears a path” to resumed growth through 2027,…
Liquidia slumps after US court rules for United Therapeutics in patent fight
Liquidia shares plunged nearly 50% on Wednesday after a federal judge ruled that its lung drug infringes key patent held by rival United Therapeutics , dealing a major blow to the treatment's commer...
Patent ruling ‘a meaningful positive’ for United Therapeutics, says RBC Capital
RBC Capital notes that the U.S. District Court for the District of Delawareissued its ruling finding that Liquidia (LQDA) has infringed Claims 1 and 14 of United Therapeutics’ (UTHR) U.S.
Liquidia shares plummet after court ruling on patent infringement claims
Shares of Liquidia (LQDA) were dropping following resumption of trade after the company confirmed the U.S. District Court for the District of Delaware ruled that two of six ‘327 patent…
Liquidia to resume trading at 1:40 pm ET
Liquidia (LQDA) is scheduled to resume trading at 1:40 pm ET, with quoting set to resume at 1:35 pm, according to Nasdaq.
Liquidia says court ruled two of six ‘327 patent claims infringed by company
Liquidia (LQDA) issued an update regarding the litigation filed by United Therapeutics (UTHR) in the U.S. District Court for the District of Delaware under the Hatch-Waxman Act concerning U.S. Patent…
Liquidia Provides Update on Hatch-Waxman Litigation Tied to ‘327 Patent
District Court ruled that two of the six claims asserted against Liquidia are valid and infringed Parties directed to submit form of judgment, specifying the proposed remedy, for the District Court's ...
Liquidia Transcript: Wells Fargo 21st Annual Healthcare Conference
YUTREPIA's launch has driven rapid revenue and patient growth, with strong adoption among naive patients and switches. The pipeline includes multiple late-stage trials, notably for L606, and expansion into new indications like PH-COPD and Raynaud's. Financial performance is robust, with a focus on sustained profitability and strategic reinvestment.
FDA Grants Fast Track Designation to YUTREPIA® for the Treatment of Raynaud's Phenomenon Associated with Systemic Sclerosis
Fast Track designation underscores the significant unmet need for patients with systemic sclerosis-associated Raynaud's phenomenon (SSc-RP), a debilitating manifestation affecting up to 90% of SSc pat...
Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 Congress
MORRISVILLE, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challeng...
Liquidia Corporation to Participate in Wells Fargo Annual Healthcare Conference
MORRISVILLE, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced that Michael Kaseta, Chief Operating Officer and Chief Financial Officer, and Jason Adair, Chi...
Liquidia Earnings Call Transcript: Q2 2026
YUTREPIA's rapid adoption drove 31% QoQ sales growth and nearly 30% market share in the inhaled prostacyclin segment, with strong profitability and cash flow supporting expanded R&D and commercial investments. The company remains confident in surpassing $1 billion in net revenue by 2027.